All In Biotech

Drug Trial Radar · NCT02362503

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)

Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 371 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

371

Actual

Start

Feb 23, 2015

Primary completion

Aug 18, 2016

Study completion Oct 22, 2026

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Feb 13, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.

Conditions

  • HIV Infections

Interventions

  • BMS-663068Drug

    BMS-663068

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized CohortTime frame: Day 1 and Day 8

Locations

139 sites in 25 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Palm Springs, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    New Haven, Connecticut

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Ft. Pierce, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Wilton Manors, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Savannah, Georgia

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Indianapolis, Indiana

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Southfield, Michigan

  • GSK Investigational Site

    Hillsborough, New Jersey

  • GSK Investigational Site

    Newark, New Jersey

  • GSK Investigational Site

    Manhasset, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Chapel Hill, North Carolina

  • GSK Investigational Site

    Durham, North Carolina

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Tulsa, Oklahoma

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Bellaire, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Buenos Aires, Argentina

Showing 40 of 139 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.